Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michaela Schneiderova is active.

Publication


Featured researches published by Michaela Schneiderova.


Carcinogenesis | 2014

HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients

Miroslav Svoboda; Jana Slyskova; Michaela Schneiderova; Peter Makovicky; Ludovit Bielik; Miroslav Levy; Ludmila Lipska; Beáta Hemmelová; Zdenek Kala; Markéta Protivánková; Ondrej Vycital; Vaclav Liska; Lucie Schwarzová; Ludmila Vodickova; Pavel Vodicka

Colorectal cancer (CRC) is one of the main causes of death of neoplasia. Demand for predictive and prognostic markers to reverse this trend is increasing. Long non-coding RNA HOTAIR (Homeobox Transcript Antisense Intergenic RNA) overexpression in tumors was previously associated with poor prognosis and higher mortality in different carcinomas. We analyzed HOTAIR expression levels in tumor and blood of incident sporadic CRC patients in relation to their overall survival with the aim to evaluate surrogate prognostic marker for CRC. Tissue donor group consisted of 73 CRC patients sampled for tumor and normal tissue. Blood donor group was represented by 84 CRC patients compared with 40 healthy controls. Patients were characterized for tumor-node-metastasis stage, tumor grade, microsatellite instability and tumor penetration by stromal cells. HOTAIR levels were assessed by real-time quantitative PCR. CRC patients had higher HOTAIR expression in blood than healthy controls (P = 0.0001), whereas there was no difference in HOTAIR levels between tumor and adjacent mucosa of CRC patients. HOTAIR levels positively correlated between blood and tumor (R = 0.43, P = 0.03). High HOTAIR levels in tumors were associated with higher mortality of patients [Coxs proportional hazard, hazard ratio = 4.4, 95% confidence interval: 1.0-19.2, P = 0.046]. The hazard ratio was even higher when blood HOTAIR levels were taken into account (hazard ratio = 5.9, 95% confidence interval: 1.3-26.1, P = 0.019). Upregulated HOTAIR relative expression in primary tumors and in blood of CRC patients is associated with unfavorable prognosis. Our data suggest that HOTAIR blood levels may serve as potential surrogate prognostic marker in sporadic CRC.


Clinical Cancer Research | 2012

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas

Jana Slyskova; Vlasta Korenkova; Andrew R. Collins; Pavel Procházka; Ludmila Vodickova; Jiri Svec; Ludmila Lipska; Miroslav Levy; Michaela Schneiderova; Vaclav Liska; Lubos Holubec; Rajiv Kumar; Pavel Soucek; Alessio Naccarati; Pavel Vodicka

Purpose: DNA repair capacity (DRC) is a determinant not only of cancer development but also of individual response to therapy. Previously, altered base and nucleotide excision repair (BER and NER) have been described in lymphocytes of patients with sporadic colorectal cancer. We, for the first time, evaluate both excision repair capacities in human colon biopsies to study their participation in colorectal tumorigenesis. Experimental design: Seventy pairs of tumor and adjacent healthy tissues were analyzed for BER- and NER-specific DRC by a comet repair assay. Tissue pairs were further compared for expression levels of a panel of 25 BER and NER genes complemented by their promoter methylation status. Results: We observed a moderate increase of NER-DRC (P = 0.019), but not of BER-DRC in tumors. There was a strong correlation between both tissues for all investigated parameters (P < 0.001). However, 4 NER (CSB, CCNH, XPA, XPD) and 4 BER (NEIL1, APEX1, OGG1, PARP1) genes showed a 1.08- to 1.28-fold change difference in expression in tumors (P < 0.05). Individual gene expression levels did not correlate with overall DRC, and we did not detect any aberrant methylation of the investigated genes. Conclusions: Our complex analysis showed that tumor cells are not deficient in BER and NER, but rather follow patterns characteristic for each individual and are comparable with adjacent tissue. Alteration of excision repair pathways is not a pronounced event in colorectal carcinogenesis. This study shows the feasibility of DRC evaluation in human solid tissues, representing a complex marker of multigene DNA repair processes. Clin Cancer Res; 18(21); 5878–87. ©2012 AACR.


Epigenomics | 2016

Epigenome-wide analysis of DNA methylation reveals a rectal cancer-specific epigenomic signature

Veronika Vymetalkova; Pavel Vodicka; Barbara Pardini; Fabio Rosa; Miroslav Levy; Michaela Schneiderova; Vaclav Liska; Ludmila Vodickova; Torbjörn K. Nilsson; Sanja A. Farkas

AIM The aim of the present study is to address a genome-wide search for novel methylation biomarkers in the rectal cancer (RC), as only scarce information on methylation profile is available. MATERIALS & METHODS We analyzed methylation status in 25 pairs of RC and adjacent healthy mucosa using the Illumina Human Methylation 450 BeadChip. RESULTS We found significantly aberrant methylation in 33 genes. After validation of our results by pyrosequencing, we found a good agreement with our findings. The BPIL3 and HBBP1 genes resulted hypomethylated in RC, whereas TIFPI2, ADHFE1, FLI1 and TLX1 were hypermethylated. An external validation by TCGA datasets confirmed the results. CONCLUSION Our study, with external validation, has demonstrated the feasibility of using specific methylated DNA signatures for developing biomarkers in RC.


BMC Cancer | 2016

Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma

Tereza Kunická; Pavel Procházka; I. Krus; Petra Bendova; M. Protivova; S. Susova; Viktor Hlavac; Vaclav Liska; P. Novak; Michaela Schneiderova; Pavel Pitule; Jan Bruha; Ondrej Vycital; Pavel Vodicka; Pavel Soucek

BackgroundThis study addresses involvement of major 5-fluorouracil (5-FU) pathway genes in the prognosis of colorectal carcinoma patients.MethodsTesting set and two validation sets comprising paired tumor and adjacent mucosa tissue samples from 151 patients were used for transcript profiling of 15 5-FU pathway genes by quantitative real-time PCR and DNA methylation profiling by high resolution melting analysis. Intratumoral molecular profiles were correlated with clinical data of patients. Protein levels of two most relevant candidate markers were assessed by immunoblotting.ResultsDownregulation of DPYD and upregulation of PPAT, UMPS, RRM2, and SLC29A1 transcripts were found in tumors compared to adjacent mucosa in testing and validation sets of patients. Low RRM2 transcript level significantly associated with poor response to the first-line palliative 5-FU-based chemotherapy in the testing set and with poor disease-free interval of patients in the validation set irrespective of 5-FU treatment. UPP2 was strongly methylated while its transcript absent in both tumors and adjacent mucosa. DPYS methylation level was significantly higher in tumor tissues compared to adjacent mucosa samples. Low intratumoral level of UPB1 methylation was prognostic for poor disease-free interval of the patients (P = 0.0002). The rest of the studied 5-FU genes were not methylated in tumors or adjacent mucosa.ConclusionsThe observed overexpression of several 5-FU activating genes and DPYD downregulation deduce that chemotherapy naïve colorectal tumors share favorable gene expression profile for 5-FU therapy. Low RRM2 transcript and UPB1 methylation levels present separate poor prognosis factors for colorectal carcinoma patients and should be further investigated.


Genes, Chromosomes and Cancer | 2018

Bleomycin-induced chromosomal damage and shortening of telomeres in peripheral blood lymphocytes of incident cancer patients.

Michal Kroupa; Zdenka Polivkova; Sivaramakrishna Rachakonda; Michaela Schneiderova; Sona Vodenkova; Tomáš Büchler; Katerina Jiraskova; Marketa Urbanova; Ludmila Vodickova; Kari Hemminki; Rajiv Kumar; Pavel Vodicka

Disruption of genomic integrity due to deficient DNA repair capacity and telomere shortening constitute hallmarks of malignant diseases. Incomplete or deficient repair of DNA double‐strand breaks (DSB) is manifested by chromosomal aberrations and their frequency reflects inter‐individual differences of response to exposure to mutagenic compounds. In this study, we investigated chromosomal integrity in peripheral blood lymphocytes (PBL) from newly diagnosed cancer patients, including 47 breast (BC) and 44 colorectal cancer (CRC) patients and 90 matched healthy controls. Mutagen sensitivity was evaluated by measuring chromatid breaks (CTAs) induced by bleomycin and supplemented by the chemiluminescent measurement of γ‐H2AX phosphorylation in 19 cancer patients (11 BC, 8 CRC). Relative telomere length (RTL) was determined in 22 BC, 32 CRC, and 64 controls. We observed statistically significant increased level of CTAs (P = .03) and increased percentage of aberrant cells (ACs) with CTAs (P = .05) in CRC patients compared with controls after bleomycin treatment. No differences were observed between BC cases and corresponding controls. CRC and BC patients with shorter RTL (below median) exhibited significantly higher amount of ACs (P = .02), CTAs (P = .02), and cells with high frequency of CTAs (≥12 CTAs/PBL; P = .03) after bleomycin treatment. No such associations were observed in healthy controls. γ‐H2AX phosphorylation after bleomycin treatment in PBL did not differ between CRC and BC patients. Our results suggest that altered DSB repair measured by sensitivity towards mutagen in PBL occurs particularly in CRC carcinogenesis. Irrespective of cancer type, telomere shortening may be associated with a decreased capacity to repair DSB.


Oncology Letters | 2015

A novel c. 204 Ile68Met germline variant in exon 2 of the mutL homolog 1 gene in a colorectal cancer patient

Pavel Vodicka; Veronika Vymetalkova; Pavel Procházka; Ludmila Vodickova; Lucie Schwarzová; Jana Slyskova; Rajiv Kumar; Michaela Schneiderova

Mutations in the mutL homolog 1 (MLH1) gene are frequent in patients with hereditary non-polyposis colorectal cancer (CRC). The MLH1 gene was screened for mutations in patients with sporadic CRC. The nucleotide sequences for all 19 exons of MLH1 were analyzed by high resolution melting and sequenced in a group of 104 sporadic CRC patients, and the results were verified in a replication group of 1,095 patients and 1,469 controls. Different melting profiles for exon 2 of the MLH1 gene were observed in the germline DNA of one patient. Sequencing of the patient’s DNA resulted in the identification of a heterozygous C>G variant at c.204, which resulted in an Ile68Met change in the amino acid. A detailed search of the National Center for Biotechnology Information and the 1000 Genomes databases indicated that the detected variant was unique. According to the SIFT and PolyPhen-2 algorithms, the substitution of Ile to Met was predicted to decrease the activity of the MLH1 protein. The newly identified, functional germline variant was not present in any other CRC patient or control. Thus, a novel germline variant in the MLH1 gene was identified, representing a rare event in sporadic CRC. The occurrence and relevance of this mutation in other types of cancer requires additional investigation.


The Journal of Nuclear Medicine | 2003

Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making

Iva Kantorova; Ludmila Lipska; Otakar Belohlavek; Vladimír Visokai; Miroslav Trubaĉ; Michaela Schneiderova


Familial Cancer | 2013

Novel mutations of the APC gene and genetic consequences of splicing mutations in the Czech FAP families

Lucie Schwarzová; Jitka Štekrová; Martina Florianová; Aleš Novotný; Michaela Schneiderova; Petr Lněnička; Věra Kebrdlová; Jaroslav Kotlas; Kamila Veselá; Milada Kohoutová


DNA Repair | 2018

Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients

Sona Vodenkova; Katerina Jiraskova; Marketa Urbanova; Michal Kroupa; Jana Slyskova; Michaela Schneiderova; Miroslav Levy; Tomáš Büchler; Vaclav Liska; Ludmila Vodickova; Veronika Vymetalkova; Andrew R. Collins; Alena Opattova; Pavel Vodicka


Carcinogenesis | 2018

Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer

Jan Král; Vlasta Korenkova; Vendula Novosadova; Lucie Langerova; Michaela Schneiderova; Vaclav Liska; Miroslav Levy; Veronika Veskrnova; Julius Spicak; Alena Opattova; Katerina Jiraskova; Veronika Vymetalkova; Pavel Vodicka; Jana Slyskova

Collaboration


Dive into the Michaela Schneiderova's collaboration.

Top Co-Authors

Avatar

Pavel Vodicka

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Ludmila Vodickova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Vaclav Liska

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Miroslav Levy

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Jana Slyskova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Katerina Jiraskova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Veronika Vymetalkova

Academy of Sciences of the Czech Republic

View shared research outputs
Top Co-Authors

Avatar

Rajiv Kumar

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Lucie Schwarzová

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Marketa Urbanova

Charles University in Prague

View shared research outputs
Researchain Logo
Decentralizing Knowledge